|
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.
|
31095341 |
2020 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Bipolar Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies common variants associated with pharmacokinetics of psychotropic drugs.
|
25944848 |
2015 |
|
Schizophrenia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies common variants associated with pharmacokinetics of psychotropic drugs.
|
25944848 |
2015 |
|
Unipolar Depression
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies common variants associated with pharmacokinetics of psychotropic drugs.
|
25944848 |
2015 |
|
Major Depressive Disorder
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study identifies common variants associated with pharmacokinetics of psychotropic drugs.
|
25944848 |
2015 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
In contrast, cortistatin, sst1, sst4, and sst5 were overexpressed in tumors, while sst3 and sst4 seemed overexpressed in less differentiated tumors.
|
29196939 |
2018 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Expression of sst(3) and sst(5) was observed in 89 and 76% of tumours respectively with highly variable levels. sst(2) mRNA expression was higher in nonfunctional tumours (P < 0.009) and sst5 was higher in pancreatic than in intestinal tumours (P < 0.02).
|
17132755 |
2006 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
VEGF and tumor vascularization were identified as novel targets for sst2-mediated antitumoral bystander effect. sst3 somatostatin receptor was upregulated in sst2-transfected tumors.
|
16218779 |
2005 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Sst2 and sst5 were expressed in 70%, sst1 in 50%, and sst3 and sst4 subtypes only in 15-20% of the tumors.
|
14602773 |
2003 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
The differential expression of sst2/sst3 receptors on gliomas and medulloblastomas has implications for the therapy of these tumours.
|
12047721 |
2002 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
Moreover, they further indicate that the presence of sst1 and sst3 transcripts might be used as an additional criterion to distinguish between seminoma and nonseminoma tumors.
|
11718451 |
2001 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
RT-PCR analysis showed the presence of sst1, sst2A, and a predominant sst3 messenger RNA (mRNA) expression in the tumor tissue.
|
10770220 |
2000 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
The comparison of SRIF receptor expression between normal tissue and seminoma tumors thus points to a selective loss of sst3 and sst4 mRNA expression in seminomas.
|
10753219 |
2000 |
|
Seminoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, they further indicate that the presence of sst1 and sst3 transcripts might be used as an additional criterion to distinguish between seminoma and nonseminoma tumors.
|
11718451 |
2001 |
|
Seminoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Altogether these data indicate that: (i) normal human testes are putative SRIF targets; (ii) loss of sst3 and sst4 SRIF receptor expression might be associated with seminoma carcinogenesis.
|
10753219 |
2000 |
|
Non-Functioning Pituitary Gland Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
A somatostatin receptor subtype-3 (SST3) peptide agonist shows antitumor effects in experimental models of Nonfunctioning Pituitary Tumors.
|
31624102 |
2020 |
|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The comparison of the three tumour entities revealed that SCLC samples had higher SST2, SST5, and CXCR4 expression, but lower SST3 and SST1 relative to ADC or SQC samples.
|
30076481 |
2018 |
|
Squamous cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The comparison of the three tumour entities revealed that SCLC samples had higher SST2, SST5, and CXCR4 expression, but lower SST3 and SST1 relative to ADC or SQC samples.
|
30076481 |
2018 |
|
Pituitary Adenoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas.
|
28384628 |
2018 |
|
Hyperglycemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Proteomic analysis of IRE-BP1 over-expression in pancreatic islet beta cells suggest IRE-BP1 (a) directly or indirectly through establishing hyperglycemia results in increased expression of ribosomal proteins and markers of ER stress and (b) leads to the enhanced and previously un-described interaction of RACK1 and TCTP.
|
27816562 |
2017 |
|
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Somatostatin decreases COX-2 expression and function in colon cancer cells via activation of sst(3) or sst(5) receptors, and these effects contribute to the inhibitory action of somatostatin on cell proliferation.
|
18587421 |
2008 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study supports the notion that IRE-BP1 may be relevant to the action of insulin in vivo and may play a role in the development of insulin resistance and diabetes.
|
18566119 |
2008 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
Our study supports the notion that IRE-BP1 may be relevant to the action of insulin in vivo and may play a role in the development of insulin resistance and diabetes.
|
18566119 |
2008 |